These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37456763)

  • 1. Updates in Cervical Cancer Screening Guidelines, The Bethesda System for Reporting Cervical Cytology, and Clinical Management Recommendations.
    Wang T; Zhang H; Liu Y; Zhao C
    J Clin Transl Pathol; 2023 Jun; 3(2):75-83. PubMed ID: 37456763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anal dysplasia screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(4):1-43. PubMed ID: 23074504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
    Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
    BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
    Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates in Cervical Cytology: The 90-Year-Long Journey from Battle Creek to Today.
    Roe CJ; Hanley KZ
    Surg Pathol Clin; 2018 Sep; 11(3):589-599. PubMed ID: 30190142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Future Role of Cytology in Cervical Cancer Screening in the Era of HPV Vaccination.
    Barroeta JE
    Acta Cytol; 2023; 67(2):111-118. PubMed ID: 36646044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cervical cancer screening: past--present--future].
    Breitenecker G
    Pathologe; 2009 Dec; 30 Suppl 2():128-35. PubMed ID: 19756616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bethesda system reporting rates, histological follow-up and HPV genotypes distribution of abnormal cytology in Anhui province of China: Analysis of 93,168 cervical liquid-based cytology test reports.
    Xu H; Chen Y; Zhao C; Wang Q; Tang M; Zhang W; Wang Q; Lou R; Liu T; Feng Y; Zhang H
    Diagn Cytopathol; 2023 Aug; 51(8):501-510. PubMed ID: 37114437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
    Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
    GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.
    Cassani B; Soldano G; Finocchiaro D; Conti S; Bulfamante A; Lemorini G; Bulfamante G
    Pathologica; 2018 Dec; 110(4):294-301. PubMed ID: 30799441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans.
    Maver PJ; Poljak M
    Clin Microbiol Infect; 2020 May; 26(5):579-583. PubMed ID: 31539637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implementation of a cervical cancer screening program via co-testing at a university hospital.
    Denninghoff V; von Petery F; Fresno C; Galarza M; Torres F; Avagnina A; Fishkel V; Krupitzki H; Fiorillo A; Monge F
    PLoS One; 2022; 17(12):e0278476. PubMed ID: 36454784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
    Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
    Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.